As its off-label use for weight loss grows in popularity, so too have concerns about potential injuries and adverse side effects
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF
Perhaps, novel mechanisms for incretin resistant patients
J.KangH.LeeY
Oral Non Peptide GLP 1 Receptor Agonist Market Size, Share & Trends Analysis by Type (Small Molecule GLP-1 Agonists, Peptide-Based Oral Formulations, Combination GLP-1 Therapies), by Application (Obesity & Weight Management, Type 2 Diabetes, Cardiovascular Risk Reduction, Non-Alcoholic Steatohepatitis (NASH)), by Distribution Channel (Retail Pharmacy, Telehealth & Direct-to-Patient, Hospital & Clinic), and Segment Forecasts, 2026 to 2035 Non-peptide oral GLP-1 receptor agonists refer to small molecules of drugs, which have the capability of activating the receptors of GLP-1 without the use of peptides as active compounds
Clinical associations: Increased lung cancer risk in smokers (slow PAH detoxification) R Increased hepatocellular carcinoma risk in aflatoxin-exposed populations R Increased susceptibility to COPD R Possible increased susceptibility to xenobiotic-induced liver damage EPHX1 His139Arg (rs2234922) This exon 4 polymorphism increases mEH activity by approximately 25%
